MindWalk Holdings Corp. has announced a breakthrough in neurodegenerative disease research, revealing the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43—a protein implicated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and certain forms of Alzheimer’s disease. This research demonstrates MindWalk’s ability to precisely distinguish between toxic and healthy protein conformations, a significant challenge in the field. The company’s approach, grounded in bio-native wet-lab validation, anchors the disease-driving structural state of proteins and converts this insight into validated biological assets. The full scientific study, “Rational Generation of Monoclonal Antibodies and Intrabodies Selective for Pathogenic TDP-43,” has already been published on bioRxiv (DOI: 10.1101/2025.06.10.658846).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindWalk Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260114327020) on January 14, 2026, and is solely responsible for the information contained therein.